ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v12i1.1244ppharm-460Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESTH17-ФЕНОТИП ЮВЕНИЛЬНОГО ИДИОПАТИЧЕСКОГО АРТРИТАTH-17 PHENOTYPE OF JUVENILE IDIOPATHIC ARTHRITISТурцевичИ. З.Turtsevich1I. Z.
аспирант кафедры педиатрии им. проф. И.М. Воронцова ФП и ДПО ГБОУ ВПО СПБГПМУ Минздрава России
iturtsevich@gmail.comНовикГ. А.NovikG. A.БычковаН. В.BychkovaN. V.КалининаН. М.KalininaN. M.ДавыдоваН. И.DavydovaN. I.Санкт-Петербургский государственный педиатрический медицинский университет Минздрава России, Российская ФедерацияРоссияSaint Petersburg State Pediatric Medical University of the Ministry of Health of Russia, Russian FederationRussian FederationВсероссийский центр экстремальной и радиационной медицины имени А.М. Никифорова МЧС России, Санкт-Петербург, Российская ФедерацияРоссияNikiforov All-Russian Center of Emergency and Radiation Medicine, Saint Petersburg, Russian FederationRussian Federation2015210820151213037Copyright © Турцевич И.З., Новик Г.А., Бычкова Н.В., Калинина Н.М., Давыдова Н.И., 20152015Турцевич И.З., Новик Г.А., Бычкова Н.В., Калинина Н.М., Давыдова Н.И.Turtsevich1 I.Z., Novik G.A., Bychkova N.V., Kalinina N.M., Davydova N.I.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/460ювенильный идиопатический артритартритTh17 клеткиIL 17АIL 1βIL 6TNF αцитокиныэнтезитассоциированный артритHLA B27системный артритjuvenile idiopathic arthritisarthritisTh17 cellsIL 17AIL 1βIL 6TNF αcytokinesenthesitis-associated arthritisHLA B27systemic arthritisReferencesAlexeeva E.I., Litvitskii P.F. Yuvenil'nyi revmatoidnyi artrit: etiologiya, patogenez, klinika, algoritmy diagnostiki i lecheniya [Juvenile Rheumatoid Arthritis: Etiology, Pathogenesis, Clinical Algorithms for Diagnosis and Treatment]. Moscow, VEDI, 2007. 368 p.Alexeeva E.I., Litvitskii P.F. Yuvenil'nyi revmatoidnyi artrit: etiologiya, patogenez, klinika, algoritmy diagnostiki i lecheniya [Juvenile Rheumatoid Arthritis: Etiology, Pathogenesis, Clinical Algorithms for Diagnosis and Treatment]. Moscow, VEDI, 2007. 368 p.Wallace C. A. Current management of juvenile idiopathic arthritis. Best Practice and Research Clinical Rheumatology. 2006; 20 (2): 279–300.Wallace C.A. Current management of juvenile idiopathic arthritis. Best Practice and Research Clinical Rheumatology. 2006; 20 (2): 279−300.Wu Q., Pesenacker A. M., Stansfield A., King D., Barge D., Foster H. E., Abinun M., Wedderburn L. R. Immunological characteristics and T cell receptor clonal diversity in children with systemic juvenile idiopathic arthritis undergoing T cell depleted autologous stem cell transplantation. Immunology. 2014; 142 (2): 227–36.Wu Q., Pesenacker A.M., Stansfield A., King D., Barge D., Foster H.E., Abinun M., Wedderburn L.R. Immunological characteristics and T cell receptor clonal diversity in children with systemic juvenile idiopathic arthritis undergoing T cell depleted autologous stem cell transplantation. Immunology. 2014; 142 (2): 227−36.Rokhlina F.V., Novik G.A., Kalinina N.M., Bychkova N.V., Filippova Yu.N., Zaraiskii M.I. Effect of MDR1 gene polymorphism S3435E on the effectiveness of treatment of juvenile idiopathic arthritis. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2013; 10 (5): 46−51.Rokhlina F.V., Novik G.A., Kalinina N.M., Bychkova N.V., Filippova Yu.N., Zaraiskii M.I. Effect of MDR1 gene polymorphism S3435E on the effectiveness of treatment of juvenile idiopathic arthritis. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2013; 10 (5): 46−51.Kurebayashi Y., Nagai S., Ikejiri A., Koyasu S. Recent advances in understanding the molecular mechanisms of the development and function of Th17 cells. Genes to Cells. 2013; 18 (4): 247–65.Kurebayashi Y., Nagai S., Ikejiri A., Koyasu S. Recent advances in understanding the molecular mechanisms of the development and function of Th17 cells. Genes to Cells. 2013; 18 (4): 247–65.Duurland C. L., Wedderburn L. R. Current developments in the use of biomarkers for juvenile idiopathic arthritis. Current Rheumatology Report. 2014; 16 (3): 406–11.Duurland C.L., Wedderburn L.R. Current developments in the use of biomarkers for juvenile idiopathic arthritis. Current Rheumatology Report. 2014; 16 (3): 406−11.Yamaguchi M. The role of regucalcin in bone homeostasis: involvement as a novel cytokine. Integrative Biology (Cambridge). 2014; 6 (3): 258–66.Yamaguchi M. The role of regucalcin in bone homeostasis: involvement as a novel cytokine. Integrative Biology (Cambridge). 2014; 6 (3): 258−66.Acosta-Rodriguez E. V., Napolitani G., Lanzavecchia A., Sallusto F. Interleukins 1_ and 6 but not transforming growth factor-_ are essential for the differentiation оf interleukin 17-producing human T helper cells. Nature immunology. 2007; 8 (9): 942–49.Acosta-Rodriguez E.V., Napolitani G., Lanzavecchia A., Sallusto F. Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation оf interleukin 17-producing human T helper cells. Nature immunology. 2007; 8 (9): 942−49.Acosta-Rodriguez E. V., Rivino L., Geginat J., Jarrossay D., Gattorno M., Lanzavecchia A., Sallusto F., Napolitani G. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nature Immunology. 2007; 8 (9): 639–46.Acosta-Rodriguez E.V., Rivino L., Geginat J., Jarrossay D., Gattorno M., Lanzavecchia A., Sallusto F., Napolitani G. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nature Immunology. 2007; 8(9): 639–46.Almanzar G., Zlamy M., Koppelstaetter C., Brunner A., Jeller V., Duftner Ch., Dejaco C., Brunner J., Prelog M. Increased replication of CD4+ naive T cells and changes in T cell homeostasis in a case of acute exacerbation of juvenile idiopathic arthritis: a case comparison study. Journal of Medical Case Reports. 2013; 7 (135): 1011–19.Almanzar G., Zlamy M., Koppelstaetter C., Brunner A., Jeller V., Duftner Ch., Dejaco C., Brunner J., Prelog M. Increased replication of CD4+ naive T cells and changes in T cell homeostasis in a case of acute exacerbation of juvenile idiopathic arthritis: a case comparison study. Journal of Medical Case Reports. 2013; 7 (135): 1011−19.Weitzmann M. N. The Role of Inflammatory Cytokines, the RANKL/OPG Axis, and the Immunoskeletal Interface in Physiological Bone Turnover and Osteoporosis. Scientifica (Cairo). 2013. Р. 705–11.Weitzmann M.N. The Role of Inflammatory Cytokines, the RANKL/OPG Axis, and the Immunoskeletal Interface in Physiological Bone Turnover and Osteoporosis. Scientifica (Cairo). 2013. Р. 705−11.Lazic E., Jelusic M., Grcevic D., Marusic A., Kovacic N. Osteoblastogenesis from synovial fluid-derived cells is related to the type of severity of juvenile idiopathic arthritis. Arthritis Research and Therapy. 2012; 14 (3): R139.Lazic E., Jelusic M., Grcevic D., Marusic A., Kovacic N. Osteoblastogenesis from synovial fluid-derived cells is related to the type of severity of juvenile idiopathic arthritis. Arthritis Research and Therapy. 2012; 14 (3): R139.Petty R. E., Southwood T. R., Manners P. et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. Journal of Rheumatology. 2004; 31 (2): 390–92.Petty R.E., Southwood T.R., Manners P. et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. Journal of Rheumatology. 2004; 31 (2): 390–92.Corrado A., Neve A., Maruotti N., Cantatore F. P. Bone Effects of Biologic Drugs in Rheumatoid Arthritis. Clinical and Developmental Immunology. 2013. Р. 105–12.Corrado A., Neve A., Maruotti N., Cantatore F.P. Bone Effects of Biologic Drugs in Rheumatoid Arthritis. Clinical and Developmental Immunology. 2013. Р. 105−12.Hueber W., Sands B. E., Lewitzky S., Vandemeulebroecke M., Reinisch W., Higgins P.D., Wehkamp J. Secukiunumab a human anti-IL-17 monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomized, double-blind, placebocontrolled trial. Gut. 2012; 61 (12): 1693–1700.Hueber W., Sands B.E., Lewitzky S., Vandemeulebroecke M., Reinisch W., Higgins P.D, Wehkamp J. Secukiunumab a human anti-IL-17 monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomized, double-blind, placebo-controlled trial. Gut. 2012; 61 (12): 1693−1700.
The authors declare that there are no conflicts of interest present.